SCHEMBL6446484

SCHEMBL6446484

CC(C)(C)c1cc(-c2ccc[nH]c2=O)c2[nH]c(=O)c(-c3ccc(N)cc3)cc2c1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALK Q9UM73 3/20 0.34
NPC1 O15118 3/20 0.34
RAB9A P51151 2/20 0.34
ATM Q13315 1/20 0.34
ERAP1 Q9NZ08 1/20 0.34
PDPK1 O15530 1/20 0.33
RET P07949 1/20 0.33
FLT3 P36888 1/20 0.33
CDK5 Q00535 1/20 0.33
CDK5R1 Q15078 1/20 0.33
NCOA1 Q15788 1/20 0.32
NCOA3 Q9Y6Q9 1/20 0.32
CYP3A4 P08684 3/20 0.32
TRPV1 Q8NER1 3/20 0.32
GBA1 P04062 1/20 0.32
TNKS O95271 1/20 0.31
AURKA O14965 1/20 0.31
AURKB Q96GD4 1/20 0.31
INCENP Q9NQS7 1/20 0.31
ALDH1A1 P00352 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1727256 0.90 TRPV1 (0.38) NPC1RAB9AATMERAP1CYP3A4
SCHEMBL10090581 0.89 ALK (0.36) ALKNPC1RAB9AATMERAP1
SCHEMBL6444232 0.89 NPC1 (0.34) NPC1RAB9AATMERAP1CYP3A4
SCHEMBL2695946 0.87 CA1 (0.40) PDPK1CYP3A4TNKSALDH1A1
SCHEMBL13186428 0.85 MAOB (0.40) ALKNPC1RAB9AATMERAP1
SCHEMBL6445454 0.83 KMT2A (0.36) NPC1RAB9AATMERAP1PDPK1
SCHEMBL2691334 0.83 CYP3A4 (0.50) PDPK1CYP3A4TRPV1ALDH1A1KDM4E
SCHEMBL2695274 0.82 PDE4A (0.41) PDPK1TRPV1
SCHEMBL3077934 0.81 GPR84 (0.38) NPC1RAB9AATMERAP1TRPV1
SCHEMBL1726478 0.81 NCOA1 (0.43) NPC1RAB9ANCOA1NCOA3KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8168792-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-05-01 US disclosed
US-20100226879-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS ABBOT SARAH C 2010-09-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100226879-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS POLR2A, IFNAR1, RRM2B ALK 3688/4885NPC1 2182/4885RAB9A 695/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.